Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

130 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Linked dual-class HIV resistance mutations are associated with treatment failure.
Boltz VF, Shao W, Bale MJ, Halvas EK, Luke B, McIntyre JA, Schooley RT, Lockman S, Currier JS, Sawe F, Hogg E, Hughes MD, Kearney MF, Coffin JM, Mellors JW. Boltz VF, et al. Among authors: hogg e. JCI Insight. 2019 Oct 3;4(19):e130118. doi: 10.1172/jci.insight.130118. JCI Insight. 2019. PMID: 31487271 Free PMC article. Clinical Trial.
Antiretroviral therapies in women after single-dose nevirapine exposure.
Lockman S, Hughes MD, McIntyre J, Zheng Y, Chipato T, Conradie F, Sawe F, Asmelash A, Hosseinipour MC, Mohapi L, Stringer E, Mngqibisa R, Siika A, Atwine D, Hakim J, Shaffer D, Kanyama C, Wools-Kaloustian K, Salata RA, Hogg E, Alston-Smith B, Walawander A, Purcelle-Smith E, Eshleman S, Rooney J, Rahim S, Mellors JW, Schooley RT, Currier JS; OCTANE A5208 Study Team. Lockman S, et al. Among authors: hogg e. N Engl J Med. 2010 Oct 14;363(16):1499-509. doi: 10.1056/NEJMoa0906626. N Engl J Med. 2010. PMID: 20942666 Free PMC article. Clinical Trial.
Timing of antiretroviral therapy for HIV-1 infection and tuberculosis.
Havlir DV, Kendall MA, Ive P, Kumwenda J, Swindells S, Qasba SS, Luetkemeyer AF, Hogg E, Rooney JF, Wu X, Hosseinipour MC, Lalloo U, Veloso VG, Some FF, Kumarasamy N, Padayatchi N, Santos BR, Reid S, Hakim J, Mohapi L, Mugyenyi P, Sanchez J, Lama JR, Pape JW, Sanchez A, Asmelash A, Moko E, Sawe F, Andersen J, Sanne I; AIDS Clinical Trials Group Study A5221. Havlir DV, et al. Among authors: hogg e. N Engl J Med. 2011 Oct 20;365(16):1482-91. doi: 10.1056/NEJMoa1013607. N Engl J Med. 2011. PMID: 22010914 Free PMC article. Clinical Trial.
Nevirapine- versus lopinavir/ritonavir-based initial therapy for HIV-1 infection among women in Africa: a randomized trial.
Lockman S, Hughes M, Sawe F, Zheng Y, McIntyre J, Chipato T, Asmelash A, Rassool M, Kimaiyo S, Shaffer D, Hosseinipour M, Mohapi L, Ssali F, Chibowa M, Amod F, Halvas E, Hogg E, Alston-Smith B, Smith L, Schooley R, Mellors J, Currier J; OCTANE (Optimal Combination Therapy After Nevirapine Exposure) ACTG A5208/OCTANE Study Team. Lockman S, et al. Among authors: hogg e. PLoS Med. 2012;9(6):e1001236. doi: 10.1371/journal.pmed.1001236. Epub 2012 Jun 12. PLoS Med. 2012. PMID: 22719231 Free PMC article. Clinical Trial.
Renal events among women treated with tenofovir/emtricitabine in combination with either lopinavir/ritonavir or nevirapine.
Mwafongo A, Nkanaunena K, Zheng Y, Hogg E, Samaneka W, Mulenga L, Siika A, Currier J, Lockman S, Hughes MD, Hosseinipour M; AIDS Clinical Trial Group (ACTG) A5208 Team. Mwafongo A, et al. Among authors: hogg e. AIDS. 2014 May 15;28(8):1135-42. doi: 10.1097/QAD.0000000000000202. AIDS. 2014. PMID: 24445367 Free PMC article. Clinical Trial.
Cardiovascular disease risk factors in HIV-infected women after initiation of lopinavir/ritonavir- and nevirapine-based antiretroviral therapy in Sub-Saharan Africa: A5208 (OCTANE).
Shaffer D, Hughes MD, Sawe F, Bao Y, Moses A, Hogg E, Lockman S, Currier J. Shaffer D, et al. Among authors: hogg e. J Acquir Immune Defic Syndr. 2014 Jun 1;66(2):155-63. doi: 10.1097/QAI.0000000000000131. J Acquir Immune Defic Syndr. 2014. PMID: 24562349 Free PMC article. Clinical Trial.
Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of inflammation or activation.
Gandhi RT, McMahon DK, Bosch RJ, Lalama CM, Cyktor JC, Macatangay BJ, Rinaldo CR, Riddler SA, Hogg E, Godfrey C, Collier AC, Eron JJ, Mellors JW; ACTG A5321 Team. Gandhi RT, et al. Among authors: hogg e. PLoS Pathog. 2017 Apr 20;13(4):e1006285. doi: 10.1371/journal.ppat.1006285. eCollection 2017 Apr. PLoS Pathog. 2017. PMID: 28426825 Free PMC article.
Cumulative Antiretroviral Exposure Measured in Hair Is Not Associated With Measures of HIV Persistence or Inflammation Among Individuals on Suppressive ART.
Gandhi M, Gandhi RT, Stefanescu A, Bosch RJ, Cyktor JC, Horng H, Louie A, Phung N, Eron JJ, Hogg E, Macatangay BJC, Hensel C, Fletcher CV, Mellors JW, McMahon DK; A5321 Team. Gandhi M, et al. Among authors: hogg e. J Infect Dis. 2018 Jun 20;218(2):234-238. doi: 10.1093/infdis/jiy011. J Infect Dis. 2018. PMID: 29529230 Free PMC article.
Persistent HIV-infected cells in cerebrospinal fluid are associated with poorer neurocognitive performance.
Spudich S, Robertson KR, Bosch RJ, Gandhi RT, Cyktor JC, Mar H, Macatangay BJ, Lalama CM, Rinaldo C, Collier AC, Godfrey C, Eron JJ, McMahon D, Jacobs JL, Koontz D, Hogg E, Vecchio A, Mellors JW. Spudich S, et al. Among authors: hogg e. J Clin Invest. 2019 Jul 15;129(8):3339-3346. doi: 10.1172/JCI127413. eCollection 2019 Jul 15. J Clin Invest. 2019. PMID: 31305262 Free PMC article. Clinical Trial.
130 results